Amicus to delay filing for U.S. marketing rights for lead drug

Amicus Therapeutics Inc said it was unlikely to submit a U.S. marketing application for its lead drug, to treat Fabry disease, by the end of 2015 as expected, after U.S. health regulators asked for a more comprehensive analysis of trial data. Amicus’s stock slumped as much as 59 percent to $5.69, at which point about $956 million had been wiped off the biotechnology company’s market capitalization on Friday. The company is hoping to make the drug, migalastat, the first oral treatment for patients with a form of Fabry disease, a potentially fatal, inherited disorder that affects about 1 in 40,000 to 60,000 men and occurs less frequently in women.
Go to Source